New England Medicine magazine released the first clinical research results of Remdesivir in the treatment of severe patients with new coronavirus pneumonia on Friday. Most patients have achieved clinical improvement, but the data of these sympathetic medications have limitations.
At present, the drug's severe clinical trials in China have been discontinued.
According to the data, Remdesivir has brought clinical improvement to 68% (36 patients) of 53 severe and dangerous recurrent coronary pneumonia patients from the United States, Europe, Canada and Japan.
Of the 57% (30/53) patients who received mechanical ventilation, 17 had extubated. A total of 47% (25/53) of patients were discharged and 13% (7/53) of patients died; among patients who received invasive ventilation, the mortality rate was 18% (6/34), while patients who did not receive invasive ventilation 5% (1/19).
It is understood that these 53 patients were treated with Remdesivir under sympathetic medication. According to the treatment plan, they will receive a 10-day Remdesivir treatment, followed by an 18-day follow-up period. The data released by this study is as of March 30, 2020.
In terms of security:
A total of 32 patients (60%) experienced side effects. The most common were elevated liver enzymes, diarrhea, rash, renal dysfunction, and hypertension.
A total of 12 (23%) patients experienced severe side effects, including multiple organ multiple organ dysfunction syndrome, septic shock, acute kidney injury, and hypertension.
Seven others died after completing Remdesivir treatment, including six patients receiving invasive ventilation and one patient receiving non-invasive oxygen support.
According to the content published by Gilead, they have learned that due to the low enrollment, Remdesivir's research on critical patients in China has been terminated early.
Special Report: Fighting The New Coronavirus
